Fiduciary Group LLC Purchases 151 Shares of Eli Lilly and Company (NYSE:LLY)

Fiduciary Group LLC boosted its position in Eli Lilly and Company (NYSE:LLY) by 2.1% in the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 7,373 shares of the company’s stock after purchasing an additional 151 shares during the period. Fiduciary Group LLC’s holdings in Eli Lilly and Company were worth $5,692,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds have also recently modified their holdings of the business. Teacher Retirement System of Texas lifted its position in shares of Eli Lilly and Company by 42.2% during the fourth quarter. Teacher Retirement System of Texas now owns 302,413 shares of the company’s stock worth $233,463,000 after purchasing an additional 89,802 shares during the last quarter. First National Bank of Hutchinson raised its position in Eli Lilly and Company by 17.1% during the 4th quarter. First National Bank of Hutchinson now owns 2,019 shares of the company’s stock valued at $1,559,000 after purchasing an additional 295 shares in the last quarter. Sandy Spring Bank raised its position in Eli Lilly and Company by 9.7% during the 4th quarter. Sandy Spring Bank now owns 21,004 shares of the company’s stock valued at $16,215,000 after purchasing an additional 1,853 shares in the last quarter. Arvest Investments Inc. raised its position in Eli Lilly and Company by 4.0% during the 4th quarter. Arvest Investments Inc. now owns 905 shares of the company’s stock valued at $699,000 after purchasing an additional 35 shares in the last quarter. Finally, Royal London Asset Management Ltd. raised its holdings in shares of Eli Lilly and Company by 2.6% in the fourth quarter. Royal London Asset Management Ltd. now owns 741,294 shares of the company’s stock valued at $572,279,000 after acquiring an additional 18,925 shares in the last quarter. 82.53% of the stock is owned by institutional investors.

Wall Street Analysts Forecast Growth

Several analysts recently weighed in on LLY shares. Morgan Stanley set a $1,146.00 price objective on Eli Lilly and Company in a report on Thursday, March 6th. StockNews.com upgraded shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a report on Friday, February 7th. Bank of America reiterated a “buy” rating and issued a $997.00 price target on shares of Eli Lilly and Company in a report on Tuesday, December 10th. Citigroup decreased their price objective on Eli Lilly and Company from $1,250.00 to $1,190.00 and set a “buy” rating for the company in a research note on Tuesday, January 28th. Finally, Leerink Partners set a $950.00 target price on Eli Lilly and Company in a research note on Friday, January 17th. Three research analysts have rated the stock with a hold rating and eighteen have assigned a buy rating to the company. Based on data from MarketBeat, the stock has a consensus rating of “Moderate Buy” and a consensus target price of $1,009.72.

Insider Transactions at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 1,000 shares of the stock in a transaction dated Thursday, March 13th. The stock was sold at an average price of $818.24, for a total transaction of $818,240.00. Following the sale, the chief accounting officer now directly owns 5,840 shares of the company’s stock, valued at approximately $4,778,521.60. This trade represents a 14.62 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Company insiders own 0.13% of the company’s stock.

Eli Lilly and Company Stock Up 1.8 %

Shares of LLY stock opened at $837.34 on Thursday. The stock’s 50-day simple moving average is $834.04 and its 200-day simple moving average is $840.69. The company has a debt-to-equity ratio of 2.00, a quick ratio of 0.97 and a current ratio of 1.15. The firm has a market capitalization of $793.94 billion, a PE ratio of 71.51, a P/E/G ratio of 1.40 and a beta of 0.34. Eli Lilly and Company has a fifty-two week low of $711.40 and a fifty-two week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Thursday, February 6th. The company reported $5.32 earnings per share for the quarter, missing the consensus estimate of $5.45 by ($0.13). Eli Lilly and Company had a return on equity of 85.24% and a net margin of 23.51%. Equities analysts expect that Eli Lilly and Company will post 23.48 earnings per share for the current year.

Eli Lilly and Company announced that its board has approved a stock repurchase program on Monday, December 9th that authorizes the company to buyback $15.00 billion in outstanding shares. This buyback authorization authorizes the company to purchase up to 2% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s leadership believes its shares are undervalued.

Eli Lilly and Company Profile

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.